60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO (mitomycin) for pyelocalyceal … [Read more…]

-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the … [Read more…]

BURLINGTON, Ontario–(BUSINESS WIRE)–Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today that there will be an additional delay in the filing of its annual information form for the year ended December 31, 2023, audited annual consolidated financial statements for the year ended December 31, 2023, the related management’s discussion and analysis of financial condition … [Read more…]

BOCA RATON, Fla.–(BUSINESS WIRE)–Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN) announced today that it is scheduled to participate in Benchmark’s Healthcare House Call Virtual One-on-One Investor Conference taking place May 21-22, 2024. William J. Burns, Executive Vice President & Chief Financial Officer and Josh Vogel, Vice President, Investor Relations, will participate in virtual one-on-one … [Read more…]

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–$ATRA #CART—Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee. This award was … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Hematology Collaboration and Licensing Deals 2016-2024” report has been added to ResearchAndMarkets.com’s offering. Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of hematology deals from 2016 to 2024. The … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)” report has been added to ResearchAndMarkets.com’s offering. The global RNAi therapeutics market is expected to record a value of US$1.39 billion in 2028, progressing at a CAGR of 9.98%, over the period 2024-2028. … [Read more…]

Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its … [Read more…]

Q1 2024 Trading Update (Unaudited) COPENHAGEN–(BUSINESS WIRE)–In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for … [Read more…]

Avantik to Serve as Primary Distribution Partner PORTSMOUTH, N.H.–(BUSINESS WIRE)–#CancerDiagnostics–Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement … [Read more…]